Ex-Genta Exec Settles SEC Insider Suit Over Melanoma Drug

By Brandon Lowrey (April 21, 2014, 10:13 PM EDT) -- A former Genta Inc. executive and two others agreed to pay penalties to resolve allegations of insider trading on confidential information about the now-defunct drugmaker's disappointing clinical tests for the experimental melanoma drug Genasense, the U.S. Securities and Exchange Commission announced Monday....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!